Blencowe Resources: Aspiring to become one of the largest graphite producers in the world. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Very Well written squadraazzura, been a holder here from 19p and wouldnt sell a share based on all this information, this company has a great future, just a little patience is needed and the outcome is obvious. Thanks for a great post. Regards John
Subject to the rubber stamping of a general meeting tomorrow , Omega has successfully raised £11m at 40p per share , and its issued capital will now be 178.2m shares , which at the current share price of 37p gives a market cap of £66m . Therefore , at the commencement of a hockey stick shaped uplift in sales , both from its 5 COVID 19 initiatives , and , most importantly , its 2 core businesses , Visitect and Food Intolerance , the company will be totally debt free . As a result of the fundraising , whether testing for antigens or antibodies , Omega’s capacity for ELISA based COVID 19 tests will go from 275/- tests per week to 1m tests per week , and its capacity for point of care lateral flow based tests will go from 100/- tests per week to 1m tests per week . Within this latter figure sits the 200/- tests per week Omega expects to be manufacturing for the HMG sponsored Rapid Test Consortium , who have just achieved design freeze of their gold standard test . Subject to imminent approvals , Visitect CD4 sales are expected to grow from a near standing start to 4m - 5m tests pa at US$4 per test and 70% gross margin within 3 - 5 years , whilst , in Food Intolerance , sales to China are expected to grow from a near standing start to US$15.5m by 2023 at 70% gross margin . The 19 minute presentation published at the time of the fundraising bears witness to how concentrated the news flow will be for the rest of this year , which I sum up below - 1) COVID 19 Antibody Tests - Mologic’s ELISA based test is already CE Marked , for sale , and being evaluated by up to 15 countries , of which India has now approved it . Mologic’s primary care focussed lateral flow test is expecting CE Marking in August with first sales in September . The HMG sponsored RTC lateral flow antibody test is awaiting PHE approval , and Omega is expecting to ship 200/- tests per week by end September . 2) COVID 19 Antigen Tests - Mologic’s ELISA based test is expected to finish development in August , achieve CE Marking in September , and first sales in October . Mologic’s lateral flow antigen test is expected to finish development in October , achieve CE Marking in November , and first sales in December . 3) Visitect CD4 - Unitaid / CHAI followed by Global Fund and PEPFAR will deploy Visitect into 4/5 countries in the Summer months . MSF , after lengthy due diligence , will deploy Visitect into various of their field sites in late Summer . Sales of Visitect to the big NGO’s await full WHO approval , which is expected in late Summer . 4) Food Intolerance in China - Self-test approval is expected in late Summer , and Omega is confident of selling 1m tests there by 2023 at US$15.5 per test , which gives a turnover aspiration of US$15.5m for China alone , comfortably more than last year’s total group Food Intolerance revenue of £9.2m . As per the above , the next 5 months promise to provide a tidal wave of news flow , which should massively underpin the share price , provide a steeply r